Developmental Core
发展核心
基本信息
- 批准号:8377544
- 负责人:
- 金额:$ 41.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-01 至 2013-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS neuropathyAIDS/HIV problemAcquired Immunodeficiency SyndromeApplications GrantsAreaAwardBasic ScienceBehaviorBiometryClinicalClinical ResearchClinical SciencesClinical TrialsClinical Trials DesignClinical Trials UnitCollaborationsDataData SetDevelopmentEducational workshopEnvironmentFacultyFellowshipFundingGenerationsGrantHIVHIV vaccineHumanImmune responseImmunologyIndustry CollaborationInstitutesInstructionInterdisciplinary StudyInternationalInterpersonal ViolenceInvestigationMentorsMissionModelingOpportunistic InfectionsOpticsOutcomePatternPneumocystis cariniiPreventionProcessRNARecruitment ActivityRelative (related person)ResearchResearch PersonnelServicesSouth AfricaStagingStrategic PlanningStructureSubstance abuse problemTrainingTranslational ResearchTravelUnited States National Institutes of HealthUniversitiesVaccine DesignVaccine ResearchVirusWorkWritingantiretroviral therapycareer developmentcohortexperiencefitnessinterestmathematical modelnanomedicinenovelpre-clinicalprogramsvaccine developmentvirology
项目摘要
The mission of the Developmental Core is to stimulate and support new HIV/AIDS research at
University of Rochester (UR). This mission will be achieved by: catalyzing new collaborative lines of
investigation; facilitating recruitment of new HIV/AIDS researchers; creating a stimulating intellectual
and scientific environment; promoting the mentoring and training of junior faculty; helping to support
international collaborations with partners in South Africa; and providing a mechanism whereby faculty
who do not presently work on HIV/AIDS can be successfully "recruited" to work on this problem.
The Core will leverage structures created for the UR's Clinical and Translational Science Institute
(CTSI). These include highly effective pilot grant award mechanisms, novel mentoring programs and
career development workshops. Five interconnected aims will be pursued. Aim 1 is to catalyze new
multidisciplinary research on HIV/AIDS. This will be achieved by funding pilot awards that support new
collaborative efforts in strategically selected "areas of opportunity" (prevention/behavior, Optics and
Nanomedicine, and international collaborations). Support will also be provided for generation of
enabling preliminary data for new grant applications and travelling fellowships. Aim 2 will focus on
recruiting new HIV/AIDS investigators. This will be achieved by providing Mentored Investigator Awards
patterned on the KO8 mechanism, with the use of experienced mentoring teams to assist young
faculty, and by supporting new faculty recruitment. The third Aim will support mentoring and career
development of young HIV/AIDS investigators. This will use the structured mentoring program
developed for the UR CTSI. Mentoring partnerships will be supervised by a Mentoring Committee of
senior D-CFAR investigators with extensive mentoring experience. A grant facilitation service will also
be initiated to provide (i) a forum for discussion and refinement of grant ideas at an early stage and (ii)
expert advice and input on written materials, with prompt turn-around. Aim 4 will create a stimulating
intellectual and scientific environment, through new seminar programs including a "Multi-Disciplinary DCFAR"
seminar, and a "HIV/AIDS Research-in-Progress" (HRIP) seminar; industry collaboration will
also be supported. Finally, the fifth aim will focus on international collaborations. Short-term instruction
in biostatistics and HIV/AIDS clinical trial design will be provided for international partners in South
Africa. In addition, a forum will be created in which UR trainees will work with datasets and research
materials from our partners in South Africa, in a mutually beneficial research collaboration. Overall,
these activities are expected to strongly enhance the HIV/AIDS research environment at UR.
发展核心的使命是刺激和支持新的艾滋病毒/艾滋病研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen Dewhurst其他文献
Stephen Dewhurst的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen Dewhurst', 18)}}的其他基金
COV-IDD: Testing for COVID-19 in high risk children with intellectual and developmental disabilities
COV-IDD:对患有智力和发育障碍的高危儿童进行 COVID-19 检测
- 批准号:
10371509 - 财政年份:2021
- 资助金额:
$ 41.56万 - 项目类别:
COV-IDD: Testing for COVID-19 in high risk children with intellectual and developmental disabilities
COV-IDD:对患有智力和发育障碍的高危儿童进行 COVID-19 检测
- 批准号:
10569140 - 财政年份:2021
- 资助金额:
$ 41.56万 - 项目类别:
Rochester Partnership to Advance Research and Academic Careers in Deaf Scholars
罗切斯特合作伙伴关系促进聋人学者的研究和学术生涯
- 批准号:
8751868 - 财政年份:2015
- 资助金额:
$ 41.56万 - 项目类别:
Rochester Partnership to Advance Research and Academic Careers in Deaf Scholars
罗切斯特合作伙伴关系促进聋人学者的研究和学术生涯
- 批准号:
9090192 - 财政年份:2015
- 资助金额:
$ 41.56万 - 项目类别:
Rochester Partnership to Advance Research and Academic Careers in Deaf Scholars
罗切斯特合作伙伴关系促进聋人学者的研究和学术生涯
- 批准号:
9895820 - 财政年份:2015
- 资助金额:
$ 41.56万 - 项目类别:
Enhanced Live Attenuated Influenza Virus With Improved Safety and Immunogenicity
增强型减毒活流感病毒,具有更高的安全性和免疫原性
- 批准号:
8883370 - 财政年份:2014
- 资助金额:
$ 41.56万 - 项目类别:
URBEST: The University of Rochester BEST Training Program
URBEST:罗彻斯特大学 BEST 培训计划
- 批准号:
8929332 - 财政年份:2014
- 资助金额:
$ 41.56万 - 项目类别:
The Semen Enhancer of HIV Infection as a Novel Microbicide Target
HIV 感染的精液增强剂作为新型杀菌剂靶标
- 批准号:
8650498 - 财政年份:2011
- 资助金额:
$ 41.56万 - 项目类别:














{{item.name}}会员




